Patients with metabolic syndrome, obesity, and type 2 diabetes frequently have non-alcoholic fatty liver disease, hypertriglyceridemia, and other lipid metabolism abnormalities, which can be somewhat improved by increasing CPT1A expression (Deprince et al., 2020). The gene discussed is CPT1A; the disease is type 2 diabetes mellitus.